S&P 500   4,344.67 (+0.42%)
DOW   34,109.52 (-0.15%)
QQQ   343.14 (+0.60%)
AAPL   166.19 (+4.38%)
MSFT   300.84 (+0.33%)
FB   295.90 (+0.43%)
GOOGL   2,599.26 (+0.74%)
AMZN   2,783.54 (-0.33%)
TSLA   841.91 (+1.55%)
NVDA   220.34 (+0.41%)
BABA   111.60 (-0.17%)
NIO   20.24 (-4.12%)
AMD   103.53 (+0.91%)
CGC   6.99 (+2.04%)
MU   77.11 (-2.05%)
GE   89.52 (-0.42%)
T   24.44 (+1.33%)
F   19.32 (-1.18%)
DIS   134.75 (-0.49%)
AMC   14.23 (-2.00%)
PFE   53.94 (+1.07%)
ACB   3.82 (+0.79%)
BA   183.92 (-3.07%)
S&P 500   4,344.67 (+0.42%)
DOW   34,109.52 (-0.15%)
QQQ   343.14 (+0.60%)
AAPL   166.19 (+4.38%)
MSFT   300.84 (+0.33%)
FB   295.90 (+0.43%)
GOOGL   2,599.26 (+0.74%)
AMZN   2,783.54 (-0.33%)
TSLA   841.91 (+1.55%)
NVDA   220.34 (+0.41%)
BABA   111.60 (-0.17%)
NIO   20.24 (-4.12%)
AMD   103.53 (+0.91%)
CGC   6.99 (+2.04%)
MU   77.11 (-2.05%)
GE   89.52 (-0.42%)
T   24.44 (+1.33%)
F   19.32 (-1.18%)
DIS   134.75 (-0.49%)
AMC   14.23 (-2.00%)
PFE   53.94 (+1.07%)
ACB   3.82 (+0.79%)
BA   183.92 (-3.07%)
S&P 500   4,344.67 (+0.42%)
DOW   34,109.52 (-0.15%)
QQQ   343.14 (+0.60%)
AAPL   166.19 (+4.38%)
MSFT   300.84 (+0.33%)
FB   295.90 (+0.43%)
GOOGL   2,599.26 (+0.74%)
AMZN   2,783.54 (-0.33%)
TSLA   841.91 (+1.55%)
NVDA   220.34 (+0.41%)
BABA   111.60 (-0.17%)
NIO   20.24 (-4.12%)
AMD   103.53 (+0.91%)
CGC   6.99 (+2.04%)
MU   77.11 (-2.05%)
GE   89.52 (-0.42%)
T   24.44 (+1.33%)
F   19.32 (-1.18%)
DIS   134.75 (-0.49%)
AMC   14.23 (-2.00%)
PFE   53.94 (+1.07%)
ACB   3.82 (+0.79%)
BA   183.92 (-3.07%)
S&P 500   4,344.67 (+0.42%)
DOW   34,109.52 (-0.15%)
QQQ   343.14 (+0.60%)
AAPL   166.19 (+4.38%)
MSFT   300.84 (+0.33%)
FB   295.90 (+0.43%)
GOOGL   2,599.26 (+0.74%)
AMZN   2,783.54 (-0.33%)
TSLA   841.91 (+1.55%)
NVDA   220.34 (+0.41%)
BABA   111.60 (-0.17%)
NIO   20.24 (-4.12%)
AMD   103.53 (+0.91%)
CGC   6.99 (+2.04%)
MU   77.11 (-2.05%)
GE   89.52 (-0.42%)
T   24.44 (+1.33%)
F   19.32 (-1.18%)
DIS   134.75 (-0.49%)
AMC   14.23 (-2.00%)
PFE   53.94 (+1.07%)
ACB   3.82 (+0.79%)
BA   183.92 (-3.07%)
NASDAQ:CRDL

Cardiol Therapeutics Stock Forecast, Price & News

$1.76
-0.12 (-6.38%)
(As of 01/28/2022 10:15 AM ET)
Add
Compare
Today's Range
$1.76
$1.83
50-Day Range
$1.68
$2.31
52-Week Range
$1.55
$4.96
Volume
5,921 shs
Average Volume
575,264 shs
Market Capitalization
$78.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive CRDL News and Ratings via Email

Sign-up to receive the latest news and ratings for Cardiol Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Cardiol Therapeutics logo

About Cardiol Therapeutics

Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on developing anti-inflammatory therapies for cardiovascular disease (CVD). Their lead product, CardiolRx, is a pharmaceutical manufactured cannabidiol formulation being investigated in a Phase II/III study in hospitalized patients testing positive for COVID-19 with a prior history of, or risk factors for CVD. The company has also initiated an international Phase II trial of CardiolR in acute myocarditis, a main cause of cardiac death in people less than 35 years old. In addition, Cardiol is developing a subcutaneous formulation of CardiolRx for the treatment of inflammation in the heart that is associated with the development and progression of heart failure. The company was founded by David Elsley, Eldon Smith, and Anthony Bolton on January 19, 2017 and is headquartered in Oakville, Canada.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Medicinal and Botanical Manufacturing
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CRDL
Web
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$78.50 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/15/2021
Today
1/28/2022
Next Earnings (Estimated)
2/21/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.73 out of 5 stars

Medical Sector

909th out of 1,417 stocks

Medicinal And Botanical Manufacturing Industry

2nd out of 4 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












Cardiol Therapeutics (NASDAQ:CRDL) Frequently Asked Questions

Is Cardiol Therapeutics a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cardiol Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Cardiol Therapeutics stock.
View analyst ratings for Cardiol Therapeutics
or view top-rated stocks.

Are investors shorting Cardiol Therapeutics?

Cardiol Therapeutics saw a decline in short interest in January. As of January 15th, there was short interest totaling 173,700 shares, a decline of 27.2% from the December 31st total of 238,600 shares. Based on an average daily volume of 723,300 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.7% of the company's stock are sold short.
View Cardiol Therapeutics' Short Interest
.

When is Cardiol Therapeutics' next earnings date?

Cardiol Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, February 21st 2022.
View our earnings forecast for Cardiol Therapeutics
.

How were Cardiol Therapeutics' earnings last quarter?

Cardiol Therapeutics Inc (NASDAQ:CRDL) released its quarterly earnings data on Monday, November, 15th. The company reported ($0.18) earnings per share (EPS) for the quarter.
View Cardiol Therapeutics' earnings history
.

What price target have analysts set for CRDL?

3 Wall Street analysts have issued twelve-month price targets for Cardiol Therapeutics' stock. Their forecasts range from $5.00 to $8.00. On average, they expect Cardiol Therapeutics' stock price to reach $6.50 in the next year. This suggests a possible upside of 269.3% from the stock's current price.
View analysts' price targets for Cardiol Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Cardiol Therapeutics' key executives?

Cardiol Therapeutics' management team includes the following people:
  • David G. Elsley, President, Chief Executive Officer & Director
  • Bernard Lim, Chief Operating Officer
  • Christopher J. Waddick, Chief Financial Officer & Secretary
  • Dan Crandall, Finance Director
  • Anthony E. Bolton, Director of Research

Who are some of Cardiol Therapeutics' key competitors?

What is Cardiol Therapeutics' stock symbol?

Cardiol Therapeutics trades on the NASDAQ under the ticker symbol "CRDL."

Who are Cardiol Therapeutics' major shareholders?

Cardiol Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Private Ocean LLC (0.05%) and Brookstone Capital Management (0.04%).

Which major investors are buying Cardiol Therapeutics stock?

CRDL stock was purchased by a variety of institutional investors in the last quarter, including Brookstone Capital Management, and Private Ocean LLC.

How do I buy shares of Cardiol Therapeutics?

Shares of CRDL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cardiol Therapeutics' stock price today?

One share of CRDL stock can currently be purchased for approximately $1.76.

How much money does Cardiol Therapeutics make?

Cardiol Therapeutics has a market capitalization of $78.50 million.

How can I contact Cardiol Therapeutics?

The company can be reached via phone at (289) 910-0850.


This page was last updated on 1/28/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.